SWY-2321

N/A

Report date: 2025/07/09 16:21:40

Base Information

Drug NameSWY-2321
Drug Alias NameSWY2321SWY-2321
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionDNA topoisomerase I inhibitorsAnti-Epidermal growth factor receptor erbB1Anti-Hepatocyte growth factor receptor
TargetsDNA topoisomerase IEpidermal growth factor receptor erbB1Hepatocyte growth factor receptor
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesCSPC Pharmaceutical Group Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCSPC Pharmaceutical Group Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A